Home » Newsletters » BioWorld Science

BioWorld Science

June 7, 1999

View Archived Issues

Company Profile: ExonHit Therapeutics

Company Profile: Cytokinetics

Licensing opportunity from Cornell Research Foundation: methods of modulating immune responses

Immunex and Genentech reach TRAIL/Apo2L oncology agreement

AVI BioPharma to initiate phase II clinical trial of Avicine in pancreatic cancer

Alteon completes phase I human trials of ALT-711

Cell Pathways updates clinical status of SAANDs

Watson reacquires North American marketing rights to Androderm

Pharming updates product pipeline

New compounds from SS Pharm. with greater bladder selectivity than oxybutynin

Pfizer claims PDE1 inhibitors for range of cardiovascular and other disorders

Kyowa Hakko presents new phosphodiesterase inhibitors

Interferon inducers in development at Hokuriku Seiyaku

Fujisawa studies inhibitors of vacuolar H+-ATPase as bone resorption inhibitors

Idec presents interim phase I/II results with clenoliximab at EULAR congress

Ligands of brain nACh receptors designed at NeuroSearch

Roche's new vitamin D derivative proves superior to calcitriol in early pharmacological testing

Lornoxicam available in Germany for arthritic conditions

SBIR award to CoCensys to discover caspase inhibitors for stroke

FDA says 3M's inhaled corticosteroid in CFC-free inhaler approvable for asthma

In vitro studies shed light on the mechanism of action of triptolide

GenVec obtains rights to patents covering HSV vectors for gene therapy in nervous system disorders

Wyeth Lederle Vaccines submits PLA for pneumococcal vaccine

Immune Response's membrane-bound cytokine-containing antitumor vaccines covered by U.S. patent

Fludarabine and other specific STAT1-targeting drugs as potential immunosuppressants

Fujisawa works to expand the clinical indications of tacrolimus

Patient treatment completed in pivotal ranolazine trial in angina

Approval recommended for nateglinide in Japan

Effects of T-588 on cerebral function studied in rats

Angiogenesis inhibitor SU-5416 poised to enter phase III testing in U.S. and Europe

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Cosmo data positive for first new hair-loss approach in decades
BioWorld
Shares of Cosmo Pharmaceuticals NV rose sharply on Dec. 3 following top-line pivotal phase III data showing a statistically significant and clinically meaningful...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...